Annual CFO
-$124.37 M
+$91.85 M+42.48%
31 December 2023
Summary:
Inovio Pharmaceuticals annual cash flow from operations is currently -$124.37 million, with the most recent change of +$91.85 million (+42.48%) on 31 December 2023. During the last 3 years, it has risen by +$53.61 million (+30.12%). INO annual CFO is now -4425.02% below its all-time high of -$2.75 million, reached on 31 December 2003.INO Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$27.44 M
+$766.10 K+2.72%
30 September 2024
Summary:
Inovio Pharmaceuticals quarterly cash flow from operations is currently -$27.44 million, with the most recent change of +$766.10 thousand (+2.72%) on 30 September 2024. Over the past year, it has increased by +$1.67 million (+5.73%). INO quarterly CFO is now -277.91% below its all-time high of $15.43 million, reached on 30 September 2015.INO Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$110.69 M
+$1.67 M+1.48%
30 September 2024
Summary:
Inovio Pharmaceuticals TTM cash flow from operations is currently -$110.69 million, with the most recent change of +$1.67 million (+1.48%) on 30 September 2024. Over the past year, it has increased by +$23.74 million (+17.66%). INO TTM CFO is now -5245.72% below its all-time high of -$2.07 million, reached on 30 June 2003.INO TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INO Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +42.5% | +5.7% | +17.7% |
| 3 y3 years | +30.1% | +41.0% | +51.7% |
| 5 y5 years | -69.1% | +1.1% | -9.2% |
INO Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +42.5% | -4.4% | +59.3% | at high | +51.7% |
| 5 y | 5 years | -69.1% | +42.5% | -99.8% | +65.0% | -21.8% | +56.9% |
| alltime | all time | -4425.0% | +42.5% | -277.9% | +65.0% | -5245.7% | +56.9% |
Inovio Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$27.44 M(-2.7%) | -$110.69 M(-1.5%) |
| June 2024 | - | -$28.21 M(-1.9%) | -$112.36 M(-3.5%) |
| Mar 2024 | - | -$28.76 M(+9.5%) | -$116.46 M(-6.4%) |
| Dec 2023 | -$124.37 M(-42.5%) | -$26.28 M(-9.7%) | -$124.37 M(-7.5%) |
| Sept 2023 | - | -$29.11 M(-9.9%) | -$134.43 M(-22.2%) |
| June 2023 | - | -$32.31 M(-11.9%) | -$172.78 M(-9.5%) |
| Mar 2023 | - | -$36.66 M(+0.9%) | -$191.00 M(-11.7%) |
| Dec 2022 | -$216.22 M(+0.2%) | -$36.34 M(-46.1%) | -$216.22 M(-0.7%) |
| Sept 2022 | - | -$67.47 M(+33.5%) | -$217.77 M(+10.7%) |
| June 2022 | - | -$50.53 M(-18.3%) | -$196.79 M(-12.4%) |
| Mar 2022 | - | -$61.88 M(+63.3%) | -$224.72 M(+4.2%) |
| Dec 2021 | -$215.71 M(+21.2%) | -$37.89 M(-18.5%) | -$215.71 M(-5.8%) |
| Sept 2021 | - | -$46.49 M(-40.7%) | -$229.03 M(-10.8%) |
| June 2021 | - | -$78.46 M(+48.4%) | -$256.70 M(+25.0%) |
| Mar 2021 | - | -$52.87 M(+3.2%) | -$205.39 M(+15.4%) |
| Dec 2020 | -$177.98 M(+81.9%) | -$51.22 M(-30.9%) | -$177.98 M(+26.7%) |
| Sept 2020 | - | -$74.16 M(+173.1%) | -$140.50 M(+49.3%) |
| June 2020 | - | -$27.15 M(+6.7%) | -$94.08 M(+3.6%) |
| Mar 2020 | - | -$25.45 M(+85.3%) | -$90.85 M(-7.2%) |
| Dec 2019 | -$97.85 M(+33.0%) | -$13.74 M(-50.5%) | -$97.85 M(-3.5%) |
| Sept 2019 | - | -$27.73 M(+15.9%) | -$101.39 M(+3.1%) |
| June 2019 | - | -$23.93 M(-26.3%) | -$98.33 M(+5.2%) |
| Mar 2019 | - | -$32.45 M(+87.8%) | -$93.43 M(+27.0%) |
| Dec 2018 | -$73.55 M(+16.4%) | -$17.28 M(-30.0%) | -$73.55 M(+4.7%) |
| Sept 2018 | - | -$24.67 M(+29.7%) | -$70.22 M(+11.7%) |
| June 2018 | - | -$19.02 M(+51.3%) | -$62.86 M(+3.8%) |
| Mar 2018 | - | -$12.58 M(-9.8%) | -$60.56 M(-4.2%) |
| Dec 2017 | -$63.21 M(+1.0%) | -$13.95 M(-19.4%) | -$63.21 M(-1.5%) |
| Sept 2017 | - | -$17.31 M(+3.6%) | -$64.16 M(-2.0%) |
| June 2017 | - | -$16.72 M(+9.8%) | -$65.49 M(+5.6%) |
| Mar 2017 | - | -$15.23 M(+2.2%) | -$62.04 M(-0.8%) |
| Dec 2016 | -$62.56 M(+402.9%) | -$14.90 M(-20.1%) | -$62.56 M(+14.9%) |
| Sept 2016 | - | -$18.64 M(+40.5%) | -$54.43 M(+167.3%) |
| June 2016 | - | -$13.27 M(-15.7%) | -$20.36 M(+26.4%) |
| Mar 2016 | - | -$15.74 M(+132.4%) | -$16.11 M(+29.5%) |
| Dec 2015 | -$12.44 M(-58.3%) | -$6.77 M(-143.9%) | -$12.44 M(-9.5%) |
| Sept 2015 | - | $15.43 M(-271.0%) | -$13.74 M(-63.1%) |
| June 2015 | - | -$9.02 M(-25.2%) | -$37.21 M(+2.4%) |
| Mar 2015 | - | -$12.07 M(+49.5%) | -$36.33 M(+21.8%) |
| Dec 2014 | -$29.82 M(+93.9%) | -$8.07 M(+0.4%) | -$29.82 M(+42.9%) |
| Sept 2014 | - | -$8.04 M(-1.3%) | -$20.87 M(+12.6%) |
| June 2014 | - | -$8.15 M(+46.6%) | -$18.54 M(+17.2%) |
| Mar 2014 | - | -$5.56 M(-735.2%) | -$15.81 M(+2.8%) |
| Dec 2013 | -$15.38 M(-31.0%) | $874.90 K(-115.3%) | -$15.38 M(-29.4%) |
| Sept 2013 | - | -$5.70 M(+5.2%) | -$21.78 M(-1.5%) |
| June 2013 | - | -$5.42 M(+5.7%) | -$22.11 M(+0.5%) |
| Mar 2013 | - | -$5.13 M(-7.1%) | -$22.00 M(-1.4%) |
| Dec 2012 | -$22.31 M(+12.9%) | -$5.52 M(-8.5%) | -$22.31 M(+4.6%) |
| Sept 2012 | - | -$6.03 M(+13.5%) | -$21.32 M(+3.7%) |
| June 2012 | - | -$5.31 M(-2.3%) | -$20.55 M(+4.4%) |
| Mar 2012 | - | -$5.44 M(+19.9%) | -$19.69 M(-0.3%) |
| Dec 2011 | -$19.76 M | -$4.53 M(-13.9%) | -$19.76 M(+6.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2011 | - | -$5.27 M(+18.3%) | -$18.57 M(+31.8%) |
| June 2011 | - | -$4.45 M(-19.1%) | -$14.09 M(+8.9%) |
| Mar 2011 | - | -$5.50 M(+64.4%) | -$12.94 M(+8.4%) |
| Dec 2010 | -$11.94 M(-15.2%) | -$3.35 M(+327.2%) | -$11.94 M(+8.4%) |
| Sept 2010 | - | -$783.70 K(-76.3%) | -$11.02 M(-24.5%) |
| June 2010 | - | -$3.30 M(-26.6%) | -$14.59 M(-10.5%) |
| Mar 2010 | - | -$4.50 M(+85.6%) | -$16.30 M(+15.7%) |
| Dec 2009 | -$14.08 M(+26.5%) | -$2.43 M(-44.4%) | -$14.08 M(-0.7%) |
| Sept 2009 | - | -$4.36 M(-12.9%) | -$14.18 M(+9.0%) |
| June 2009 | - | -$5.01 M(+119.1%) | -$13.01 M(+17.9%) |
| Mar 2009 | - | -$2.29 M(-9.7%) | -$11.03 M(-0.8%) |
| Dec 2008 | -$11.13 M(-3.4%) | -$2.53 M(-20.7%) | -$11.13 M(+15.8%) |
| Sept 2008 | - | -$3.19 M(+5.3%) | -$9.61 M(+1.0%) |
| June 2008 | - | -$3.03 M(+27.4%) | -$9.51 M(-4.9%) |
| Mar 2008 | - | -$2.38 M(+134.9%) | -$10.00 M(-13.1%) |
| Dec 2007 | -$11.51 M(+63.5%) | -$1.01 M(-67.3%) | -$11.51 M(+33.9%) |
| Sept 2007 | - | -$3.09 M(-12.2%) | -$8.60 M(+0.2%) |
| June 2007 | - | -$3.52 M(-9.5%) | -$8.58 M(+5.8%) |
| Mar 2007 | - | -$3.89 M(-304.2%) | -$8.10 M(+15.1%) |
| Dec 2006 | -$7.04 M(-42.8%) | $1.91 M(-162.0%) | -$7.04 M(-38.2%) |
| Sept 2006 | - | -$3.07 M(+0.9%) | -$11.40 M(+14.6%) |
| June 2006 | - | -$3.05 M(+7.7%) | -$9.95 M(-13.9%) |
| Mar 2006 | - | -$2.83 M(+15.4%) | -$11.55 M(-6.1%) |
| Dec 2005 | -$12.31 M(+81.0%) | -$2.45 M(+51.3%) | -$12.31 M(+1.0%) |
| Sept 2005 | - | -$1.62 M(-65.1%) | -$12.19 M(-3.8%) |
| June 2005 | - | -$4.65 M(+29.7%) | -$12.67 M(+41.9%) |
| Mar 2005 | - | -$3.58 M(+53.6%) | -$8.92 M(+31.2%) |
| Dec 2004 | -$6.80 M(+147.4%) | -$2.33 M(+11.3%) | -$6.80 M(+13.2%) |
| Sept 2004 | - | -$2.10 M(+131.0%) | -$6.01 M(+17.2%) |
| June 2004 | - | -$907.50 K(-37.9%) | -$5.13 M(-5.2%) |
| Mar 2004 | - | -$1.46 M(-5.2%) | -$5.41 M(+96.8%) |
| Dec 2003 | -$2.75 M(-44.6%) | -$1.54 M(+26.9%) | -$2.75 M(+17.6%) |
| Sept 2003 | - | -$1.22 M(+2.2%) | -$2.34 M(+12.9%) |
| June 2003 | - | -$1.19 M(-199.3%) | -$2.07 M(-16.4%) |
| Mar 2003 | - | $1.20 M(-205.8%) | -$2.48 M(-50.1%) |
| Dec 2002 | -$4.96 M(-0.5%) | -$1.13 M(+19.4%) | -$4.96 M(+29.6%) |
| Sept 2002 | - | -$947.60 K(-40.6%) | -$3.83 M(-13.3%) |
| June 2002 | - | -$1.59 M(+24.0%) | -$4.42 M(-15.9%) |
| Mar 2002 | - | -$1.29 M(-16.4%) | -$5.26 M(-35.7%) |
| Dec 2001 | -$4.98 M(-40.6%) | - | - |
| Sept 2001 | - | -$1.54 M(-36.8%) | -$8.18 M(-6.6%) |
| June 2001 | - | -$2.43 M(+5.1%) | -$8.76 M(+4.4%) |
| Mar 2001 | - | -$2.31 M(+22.1%) | -$8.40 M(+4.0%) |
| Mar 2001 | -$8.40 M(-4.5%) | - | - |
| Dec 2000 | - | -$1.90 M(-10.5%) | -$8.07 M(+1.2%) |
| Sept 2000 | - | -$2.12 M(+2.5%) | -$7.98 M(+1.5%) |
| June 2000 | - | -$2.07 M(+3.8%) | -$7.86 M(-10.6%) |
| Mar 2000 | -$8.79 M(+39.5%) | -$1.99 M(+10.6%) | -$8.79 M(+29.3%) |
| Dec 1999 | - | -$1.80 M(-10.0%) | -$6.80 M(+36.0%) |
| Sept 1999 | - | -$2.00 M(-33.3%) | -$5.00 M(+66.7%) |
| June 1999 | - | -$3.00 M | -$3.00 M |
| Mar 1999 | -$6.30 M | - | - |
FAQ
- What is Inovio Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Inovio Pharmaceuticals?
- What is Inovio Pharmaceuticals annual CFO year-on-year change?
- What is Inovio Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Inovio Pharmaceuticals?
- What is Inovio Pharmaceuticals quarterly CFO year-on-year change?
- What is Inovio Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Inovio Pharmaceuticals?
- What is Inovio Pharmaceuticals TTM CFO year-on-year change?
What is Inovio Pharmaceuticals annual cash flow from operations?
The current annual CFO of INO is -$124.37 M
What is the all time high annual CFO for Inovio Pharmaceuticals?
Inovio Pharmaceuticals all-time high annual cash flow from operations is -$2.75 M
What is Inovio Pharmaceuticals annual CFO year-on-year change?
Over the past year, INO annual cash flow from operations has changed by +$91.85 M (+42.48%)
What is Inovio Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of INO is -$27.44 M
What is the all time high quarterly CFO for Inovio Pharmaceuticals?
Inovio Pharmaceuticals all-time high quarterly cash flow from operations is $15.43 M
What is Inovio Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, INO quarterly cash flow from operations has changed by +$1.67 M (+5.73%)
What is Inovio Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of INO is -$110.69 M
What is the all time high TTM CFO for Inovio Pharmaceuticals?
Inovio Pharmaceuticals all-time high TTM cash flow from operations is -$2.07 M
What is Inovio Pharmaceuticals TTM CFO year-on-year change?
Over the past year, INO TTM cash flow from operations has changed by +$23.74 M (+17.66%)